Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Impression Healthcare has successfully registered its first clinical trial to investigate the effects of its Cannabidiol (CBD) toothpaste and mouthwash on Gum Disease
  • The trial is a world first for the assessment of CBD on Gingivitis and Periodontitis
  • Approximately five million Australians and almost 40 per cent of Australians aged 55 and over have moderate to severe gum disease or Periodontitis
  • Registration of the trial marks the formal commencement of the trial as per Impression’s commitment with Cannvalate
  • Three other clinical trials for the investigation of cannabis medicines into sleep apnoea, concussion remediation and TMJ Disorders are also progressing and on track to commence in Q3 CY2019
  • IHL will now formalise approval from the Human Research Ethics Committee, prior to patient recruitment and dosing

Impression Healthcare has successfully registered its first clinical trial to investigate the effects of its Cannabidiol (CBD) toothpaste and mouthwash on Gum Disease.

The completed trial protocol has been submitted to and registered on the Australian and New Zealand Clinical Trials Registry (ANZCTR). The company will now formalise all approvals before recruiting and dosing patients.

“Formal registration of the gingivitis and periodontitis trialrepresents significant progress in IHL’s medicinal cannabis activities and is the culmination of many months of work by our team and research partners,” CEO Joel Latham, said.

The trial is considered a phase 2a randomised controlled clinical trial designed to investigate clinical efficacy and safety.

Approximately five million Australians and almost 40 per cent of Australians aged 55 and over have moderate to severe gum disease or Periodontitis.

The trial will comprise 40 participants who will use the CBD toothpaste and mouthwash three times daily over a 30-day period. Gum inflammation will initially be induced and then monitored as Cannabidiol is a powerful suppressor of inflammation.

After five days of treatment, the patients’ gum health will be measured using the gingivitis bleeding index and then again after the 30-day trial period.

IHL is working with AXIM Biotechnologies Incorporated who will provide the products for the clinical trials and also facilitate commercial sales under a royalty arrangement.

In March 2019, IHL executed a binding collaboration agreement with Cannvalate and Swinburne University of Technology to undertake four medicinal cannabis clinical trials. The trials include using Cannabidiol for the treatment of Temporomandibular Joint Dysfunction (TJD), concussions, sleep apnoea and gum disease.

“We are excited to have assembled highly qualified researchers for a world first trial for the use of CBD in treatment of Gingivitis and Gum Disease, which are major problems representing a major market,” Joel said.

Patient recruitment for the gum disease trials will commence in August followed by the 30-day trial.

IHL by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

" Dimerix (ASX:DXB) receives approvals to start Phase 3 kidney damage trial

Dimerix (DXB) has been granted Australian ethics and regulatory approval for its Phase 3 clinical trial in FSGS kidney patients.